+

WO1990000556A1 - Synthetic hiv protease gene and method for its expression - Google Patents

Synthetic hiv protease gene and method for its expression Download PDF

Info

Publication number
WO1990000556A1
WO1990000556A1 PCT/US1989/002996 US8902996W WO9000556A1 WO 1990000556 A1 WO1990000556 A1 WO 1990000556A1 US 8902996 W US8902996 W US 8902996W WO 9000556 A1 WO9000556 A1 WO 9000556A1
Authority
WO
WIPO (PCT)
Prior art keywords
protease
gene
hiv
expression
synthetic
Prior art date
Application number
PCT/US1989/002996
Other languages
French (fr)
Inventor
John M. Louis
Stephen Oroszlan
Peter T. Mora
Original Assignee
The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce filed Critical The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce
Publication of WO1990000556A1 publication Critical patent/WO1990000556A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to synthetic genes and their expression products. Specifically, this
  • invention relates to a synthetic protease gene and its expression product.
  • protease protein in purified virion preparation was shown only by immunological techniques.
  • the HIV protease sequence together with the gag and pol sequence or fusion proteins have been expressed from viral DNA in bacteria. Examples of such disclosures include: 1. Henderson, et al., 1988, "Human Retroviruses, Cancer and AIDS: Approaches to Prevention and Therapy", D. Boloqnesi Ed. Published by Alan R. Liss Inc., New York, NY. pp.135-147;
  • the primary sequences of the HIV protease has been determined by protein analysis and by the
  • protease is a 99 amino acid long protein encoded by a 297bp long stretch of the HIV provirus. All previous experiments on the protease gene and on its expression were carried out by
  • nucleotide sequences cloned out from the cDNA of the provirus The inventors' work using synthetic DNA proves that the nucleotide sequence of the provirus DNA and also the deduced aminoacid sequence are
  • the sequence coding for the protease in the pol open reading frame of HIV was determined by previous analysis and corresponds to nucleotide 1609 to 1906 The N terminus and the C terminal amino-acids are proline and phenylalanine respectively.
  • This sequence coding for the HIV-I 99 aminoacid protease is 297bp long as follows.
  • HIV human immunodeficiency virus
  • the invention is a gene for encoding a protease of human immunodeficiency virus.
  • the gene consists essentially of a synthetic nucleotide sequence for a protease essential to infectivity of human immunodeficiency virus.
  • the protease is desirably a protease of HIV-1 or HIV-2 that is essential for the infectivity of these viruses.
  • HIV-1 protease expression of the HIV-1 protease is represented above by the top rows of nucleotide sequence.
  • Figure 1 presents the expressed HIV protease as analyzed in Western blot.
  • Figure 2 illustrates a strategy for the synthesis of the HIV-1 protease gene.
  • the 3' overhangs are in lower case.
  • the complementary strands (not shown) were provided with 3' overhangs to match the coding strands.
  • Figure 3 illustrates the induction of the gene at various periods of time.
  • Figure 4 illustrates the activity of the expressed protease using a synthetic peptide asa substrate.
  • the invention is a synthetic DNA sequence for encoding a specific enzyme or protease.
  • the protease is essential for the infectivity of the human
  • HIV immunodeficiency virus
  • the invention also includes synthesis and expression of the protease gene of other retroviruses such as HIV-2, the human leukemia viruses such as HTLV I, II, and other human and animal RNA containing viruses causing leukemia sarcoma and other malignencies.
  • nucleotide sequence for the preferred embodiment of this invention was obtained from a published paper by Ratner, et al., supra.
  • the sequence in the pol open reading frame coding for the protease of HIV-1 corresponds to nucleotide 1609 to 1906.
  • the N-terminal and the C-terminal amino-acids are proline and phenylalanine respectively.
  • This sequence coding for the 99 aminoacid protease is 297bp long as shown above. Minor substitutions of one or more bases in this and other genes useful in this invention can produce a variant gene capable of expressing the desired
  • a procaryotic expression vector was used to clone and then to express the synthetic sequence coding for the protease.
  • the expression can be in prokaryotes (bacteria) or in other appropriate expression systems.
  • Recombinant clones screened by colony hybridization using a labelled fragment (62bp) spanning the internal region of the protease gene. Positive clones were further analyzed for the size of the insert. Clones which answered positive were induced for expression and analyzed in Western blots to determine the protein product using specific antibodies.
  • Figure 1 gives an example.
  • the gene product has specific protease activity, as it is capable of cleaving both synthetic and natural substrates.
  • the enzyme has been purified by specific column chromatographic techniques, including affinity chromotography.
  • the method of this invention can produce enough active protease to study the structure of the protease, its mechanisms of
  • Figure 1 demonstrates the expression of the HIV protease in E. coli.
  • Cells transformed with the synthetic sequence of HIV protease in an appropriate expression vector were induced and the bacterial lysate was electrophoresed in SDS-PAGE. After transfer of proteins into a nitrocellulose membrane, immunoblotting procedure was performed using the specific antibody to the HIV protease. Detection of Ag-Ab complex was made using I 125 protein A. The autoradiograph lane A
  • the 11.5 kd band is the protease.
  • the synthetic DNA of the invention also obviates any need to manipulate (infectious) viral material and overcomes limitations in the quantities which can be obtained by other means.
  • Plasmid PKK233-2 a procaryotic expression vector was purchased from Pharmacia. PKK233-2 was used to transform in a laq-q host, E. coli cell JM105 or RB791. The cells were selected in M9 minimal media containing lug/ml thiamine, prior to using them for transformation. All chemicals utilized in the
  • oligonucleotides were from Applied Biosystems Inc. T4 polynucleotide kinase, DNA ligase, and Klenow fragment of E. coli DNA polymerase I were obtained from New England Biolabs. Restriction
  • DNA fragments were synthesized using a ABI DNA synthesizer (model 381A). All synthetic fragments were purified by electrophoresis in a 12%
  • the polyclonal antibodies were raised in rabbits against (i) a complete synthetic sequence of 1 to 99 aminoacids of the HIV-1 protease and (ii) a tridecapeptide corresponding to the C-terminus of the protease.
  • E. coli cells bearing the appropriate plasmid construct were grown to log phase, induced, and lysed by sonication. Total cell extracts were analysed by NaDodSO 4 /PAGE and subjected to immunoblot analysis.
  • Oligopeptides were synthesized in a Peptide Synthesizer (Applied Biosystems Model 430A), according to the method previously published (Copeland and
  • This example represents the preferred embodiment.
  • the nucleotide sequence of the protease gene was taken from Ratner et al.
  • the sequence in the pol open reading frame for the protease gene starts at nucleotide 1609 and ends at 1906, for coding 99 aminoacids. This sequence and its complement were synthesized as five individual fragments of
  • Figure 3 shows examples of Western blot analysis of the gene product.
  • Figure 3 illustrates expression of the synthetic protease gene in E. coli. Clone PR-C bearing the coding sequence to the protease was induced for expression. The proteins (75ug of bacterial extract) were electrophoresed in a NaDodSO 4 /PAGE transferred to nitrocellulose and subjected to immunoblot analysis using a mixture of the two protease specific rabbit polyclonal antibodies raised against (i) a complete synthetic sequence of 1-99 amino acids of the HIV-1 protease and (ii) a tridecapeptide corresponding to the C terminus of the protease.
  • Figure 3A shows the induction of the gene with 0.4mM IPTG at various periods of time.
  • Figure 3B shows the induction for 30 minutes.
  • FIG. 1-5 represent mM concentration of IPTG at 0.28, 0.56, 1.12, 2.24 and 4.48 respectively.
  • Figure 3C shows the analysis after 60 minutes of induction with ImM IPTG and lysing the cells in various buffers.
  • B1 denotes lysis of cells in 50mM Tris-HCl at pH 7.0, 150mM NaCl, ImM EDTA, ImM PMST, ImM DTT and 0.5 percent NP-40.
  • B2 is the same as B1, but without NaCl and
  • B3 is in 50mM potassium phosphate at pH 6.0, ImM PMSF and ImM DTT.
  • B4 is the same as B3 with a pH of 6.5. Positions of protein molecular weight markers are inducated on the left in kilodaltons.
  • E. coli cells bearing plasmid PR-C were grown in Luria broth to an optical density of 0.4 A600nm, and then induced at various periods of time for expression from the trc promotor by adding IPTG (isopropyl-beta-D-thiog-alactopyranoside) at a concentration of 0.4mM as seen in Figure 3A.
  • IPTG isopropyl-beta-D-thiog-alactopyranoside
  • the cloned gene expressed a single, unfused protein band of 11.5kd. Expression was maximal after 30 minutes of induction. This level decreased to about 25 percent at 60 minutes. There was no
  • Figure 4 illustrates the activity of the expressed protease using a synthetic peptide as a substrate. Protease assays were carried out with
  • reaction buffer was mixed with aliquots of various cell extracts (see description of Figure 4 above) and incubated at 37°C. Equal eliquots of incubation mixture were taken at various time points and analyzed by RP-HPLC. The substrate in the 0 hour sample eluted as a single peak as shown in Figure 4A. After incubation for 1 hour, two newly appearing peaks, products
  • Pro-Ile-Val-Glu-NH 2 is substantially smaller than that of the pentapeptide having a free
  • the amino acid composition data for the substrate and its cleavage products are shown in Table 1.
  • the amounts of observed amino acids correspond clearly to the expected amounts demonstrating that the cleavage occurs at the expected cleavage site of the synthetic peptide corresponding to the pl7-p24 site of the gag precursor.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention is a synthetic DNA sequence for encoding a specific enzyme or protease. The protease is essential for the completion (replication) of an infective human immunodeficiency virus (HIV). The invented gene is desirable for the expression of the protease by recombinant methodology in prokaryotic and/or eukaryotic cells and the production of a commercially desirable amount of the protease for biochemical and physical characterization, necessary to find effective inhibitor of the protease, and thereby to block the production of infectious human immunodeficiency virus (HIVs).

Description

SYNTHETIC HIV PROTEASE GENE
AND METHOD FOR ITS EXPRESSION
BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates to synthetic genes and their expression products. Specifically, this
invention relates to a synthetic protease gene and its expression product.
Description of the Related Art
The presence of protease protein in purified virion preparation was shown only by immunological techniques. The HIV protease sequence together with the gag and pol sequence or fusion proteins have been expressed from viral DNA in bacteria. Examples of such disclosures include: 1. Henderson, et al., 1988, "Human Retroviruses, Cancer and AIDS: Approaches to Prevention and Therapy", D. Boloqnesi Ed. Published by Alan R. Liss Inc., New York, NY. pp.135-147;
2. Debouck, et al., 1987, P.N.A.S.. 84: 8903-8906, and 3. Mous, et al., 1988, J. Virol, 62:1433-1436.
The primary sequences of the HIV protease has been determined by protein analysis and by the
nucleotide sequence of the proviral DNA. It was thus determined that the protease is a 99 amino acid long protein encoded by a 297bp long stretch of the HIV provirus. All previous experiments on the protease gene and on its expression were carried out by
utilizing nucleotide sequences cloned out from the cDNA of the provirus. The inventors' work using synthetic DNA proves that the nucleotide sequence of the provirus DNA and also the deduced aminoacid sequence are
correct.
The complete nucleotide sequence of the HIV-1 proviral DNA was published by Ratner et al., 1985,
Nature, 313:277-284. The sequence coding for the protease in the pol open reading frame of HIV was determined by previous analysis and corresponds to nucleotide 1609 to 1906 The N terminus and the C terminal amino-acids are proline and phenylalanine respectively. This sequence coding for the HIV-I 99 aminoacid protease is 297bp long as follows.
10 20 30 40 50 CCTCAGATCA CTCTTTGGCA ACGACCCCTC GTCACAATAA AGATAGGGGG GGAGTCTAGT GAGAAACCGT TGCTGGGGAG CAGTGTTATT TCTATCCCCC
60 70 80 90 100
GCAACTAAAG GAAGCTCTAT TAGATACAGG AGCAGATGAT ACAGTATTAG CGTTGATTTC CTTCGAGATA ATCTATGTCC TCGTCTACTA TGTCATAATC
110 120 130 140 150
AAGAAATGAG TTTGCCAGGA AGATGGAAAC CAAAAATGAT AGGGGGAATT TTCTTTACTC AAACGGTCCT TCTACCTTTG GTTTTTACTA TCCCCCTTAA
160 170 180 190 200
GGAGGTTTTA TCAAAGTAAG ACAGTATGAT CAGATACTCA TAGAAATCTG CCTCCAAAAT AGTTTCATTC TGTCATACTA GTCTATGAGT ATCTTTAGAC
210 220 230 240 250
TGGACATAAA GCTATAGGTA CAGTATTAGT AGGACCTACA CCTGTCAACA ACCTGTATTT CGATATCCAT GTCATAATCA TCCTGGATGT GGACAGTTGT
260 270 280 290
TAATTGGAAG AAATCTGTTG ACTCAGATTG GTTGCACTTT AAATTTT ATTAACCTTC TTTAGACAAC TGAGTCTAAC CAACGTGAAA TTTAAAA
The industry is lacking a synthetic DNA sequence that encodes a specific enzyme or protease which is essential for the completion replication) of an infective human immunodeficiency virus (HIV). This DNA sequence is desirable to express this protease by recombinant methodology in bacteria and or in eukaryotic cells, and to produce enough protease for biochemical and physical characterization in order to design and produce potent inhibitors of this enzyme, and thereby to block the production of infective HIV particles.
BRIEF DESCRIPTION OF THE INVENTION
The invention is a gene for encoding a protease of human immunodeficiency virus. The gene consists essentially of a synthetic nucleotide sequence for a protease essential to infectivity of human immunodeficiency virus.
The protease is desirably a protease of HIV-1 or HIV-2 that is essential for the infectivity of these viruses.
The preferred embodiment of this inventions is a synthetic gene and the coding sequence for
expression of the HIV-1 protease is represented above by the top rows of nucleotide sequence.
BRIEF DESCRIPTION OF THE DRAWING
Figure 1 presents the expressed HIV protease as analyzed in Western blot.
Figure 2 illustrates a strategy for the synthesis of the HIV-1 protease gene. The 3' overhangs are in lower case. The complementary strands (not shown) were provided with 3' overhangs to match the coding strands.
Figure 3 illustrates the induction of the gene at various periods of time.
Figure 4 illustrates the activity of the expressed protease using a synthetic peptide asa substrate.
DESCRIPTION OF THE PREFERRED EMBODIMENT
The invention is a synthetic DNA sequence for encoding a specific enzyme or protease. The protease is essential for the infectivity of the human
immunodeficiency virus (HIV). The invented gene is desirable for the expression of the protease by
recombinant methodology in bacteria and or in
eukaryotic cells and the production of a commercially desirable amount of the protease for biochemical and physical characterization. This characterization is necessary for the design and production of potent inhibitors of this enzyme. The invention also includes synthesis and expression of the protease gene of other retroviruses such as HIV-2, the human leukemia viruses such as HTLV I, II, and other human and animal RNA containing viruses causing leukemia sarcoma and other malignencies.
The nucleotide sequence for the preferred embodiment of this invention was obtained from a published paper by Ratner, et al., supra. The sequence in the pol open reading frame coding for the protease of HIV-1 corresponds to nucleotide 1609 to 1906. The N-terminal and the C-terminal amino-acids are proline and phenylalanine respectively. This sequence coding for the 99 aminoacid protease is 297bp long as shown above. Minor substitutions of one or more bases in this and other genes useful in this invention can produce a variant gene capable of expressing the desired
protease.
This sequence was synthesized as five
fragments using the DNA synthesizer. Complementary strands corresponding to these five fragments were also synthesized. The 3' overhangs of four bases were provided for appropriate sequences to efficiently ligate each of the five fragments and to provide the correct coding sequence of the protease gene. Nucleotide ATG were added to the fragment corresponding to the 5' end of the gene and TAA at the 3' end.
A procaryotic expression vector was used to clone and then to express the synthetic sequence coding for the protease. The expression can be in prokaryotes (bacteria) or in other appropriate expression systems. Recombinant clones screened by colony hybridization using a labelled fragment (62bp) spanning the internal region of the protease gene. Positive clones were further analyzed for the size of the insert. Clones which answered positive were induced for expression and analyzed in Western blots to determine the protein product using specific antibodies. Figure 1 gives an example.
Of the clones screened so far, 3 clones have been identified to express a product of 11.5kd,
reacting against specific antibodies as illustrated in Figure 1.
Conditions for the induction of a protease gene were studied in E. coli and optimized. The
inventors have shown that the gene product has specific protease activity, as it is capable of cleaving both synthetic and natural substrates. The enzyme has been purified by specific column chromatographic techniques, including affinity chromotography. The method of this invention can produce enough active protease to study the structure of the protease, its mechanisms of
action, with a goal of devising specific inhibitors to this enzyme, of a therapeutic application for the
treatment of the diseases, such as AIDS, caused by the viruses. Other embodiments of this invention can
utilize a gene to express another protease such as the following gene for the HIV-2 protease.
CCTCAATTCTCTCTTTGGAAAAGACCAGTAGTCACAGCATACATTGAGGGTCAGCCA GTAGAAGTCTTGTTAGACACAGGGGCTGACGACTCAATAGTAGCAGGAATAGAGTTA GGGAACAATTATAGCCCAAAAATAGTAGGGGGAATAGGGGGATTCATAAATACCAAG GAATATAAAAATGTAGAAATAGAAGTTCTAAATAAAAAGGTACGGGCCACCATAATG ACAGGCGACACCCAATCAACATTTTTGGCAGAAATATTCTGACAGCCTTAGGCATGT CATTAAATCTAC
Figure 1 demonstrates the expression of the HIV protease in E. coli. Cells transformed with the synthetic sequence of HIV protease in an appropriate expression vector were induced and the bacterial lysate was electrophoresed in SDS-PAGE. After transfer of proteins into a nitrocellulose membrane, immunoblotting procedure was performed using the specific antibody to the HIV protease. Detection of Ag-Ab complex was made using I125 protein A. The autoradiograph lane A
represents E. coli transformed with the plasmid, and lanes B and C E. coli transformed with the plasmid bearing synthetic DNA encoding the HIV protease. On the left are protein molecular weight markers in
kilodalton. The 11.5 kd band is the protease.
The synthetic DNA of the invention also obviates any need to manipulate (infectious) viral material and overcomes limitations in the quantities which can be obtained by other means.
EXAMPLES
The following materials and methods were used to perform the examples.
PLASMID, BACTERIAL STRAINS. AND CHEMICALS:
Plasmid PKK233-2, a procaryotic expression vector was purchased from Pharmacia. PKK233-2 was used to transform in a laq-q host, E. coli cell JM105 or RB791. The cells were selected in M9 minimal media containing lug/ml thiamine, prior to using them for transformation. All chemicals utilized in the
synthesis of oligonucleotides were from Applied Biosystems Inc. T4 polynucleotide kinase, DNA ligase, and Klenow fragment of E. coli DNA polymerase I were obtained from New England Biolabs. Restriction
endonucleases, PMSF and IPTG were from Boehringer Mannheim, Bethesda Research Laboratories and
Promega respectively.
DNA SYNTHESIS. PLASMID CONSTRUCTION AND SCREENING:
DNA fragments were synthesized using a ABI DNA synthesizer (model 381A). All synthetic fragments were purified by electrophoresis in a 12%
polyacrylamide/8M urea sequencing gel. DNA was visualized by UV-shadowing and full-length fragments were eluted from the gel as known in the art. The full-length fragments were checked for their purity using standard techniques.
Appropriate complementary fragments were mixed in equimolar concentrations, annealed, kinased and ligated as described elsewhere. The efficiency of ligation was monitored by polyacrylamide gel
lectrophoresis. The linearized plasmid and the protease gene in appropriate concentrations were ligated and used for transformation of E. coli. JM105. Recombinant clones were screened by colony
hybridization using a 62 bp fragment labelled by kinasing. Small scale isolation of plasmid DNA from the recombinant clones was performed by the boiling method and the size of the inserts was visualized by autoradiography after labelling the 3' recessed terminal using the Klenow fragment of E. coli DNA polymerase.
ANTIBODIES TO THE HIV PROTEASE
The polyclonal antibodies were raised in rabbits against (i) a complete synthetic sequence of 1 to 99 aminoacids of the HIV-1 protease and (ii) a tridecapeptide corresponding to the C-terminus of the protease.
ANALYSIS OF THE EXPRESSED PROTEINS
E. coli cells bearing the appropriate plasmid construct were grown to log phase, induced, and lysed by sonication. Total cell extracts were analysed by NaDodSO4/PAGE and subjected to immunoblot analysis. ASSAY FOR THE ACTIVITY OF THE EXPRESSED PROTEASE:
Oligopeptides were synthesized in a Peptide Synthesizer (Applied Biosystems Model 430A), according to the method previously published (Copeland and
Oroszlan, 1981). The cleavage products were analysed by RP-HPLC on a uBondapak c18 column (Waters
Associates). Peak fractions were analysed for amino-acid composition using a Pico-Tag amino acid analyser (Waters Associates).
EXAMPLE 1
This example represents the preferred embodiment.
RESULTS :
SYNTHESIS OF THE FULL-LENGTH PROTEASE GENE:
The nucleotide sequence of the protease gene was taken from Ratner et al. The sequence in the pol open reading frame for the protease gene starts at nucleotide 1609 and ends at 1906, for coding 99 aminoacids. This sequence and its complement were synthesized as five individual fragments of
approximately 60 bases as shown in Figure 2. The 3' overhangs of 4 bases (shown in lower case) were provided for the fragments to selectively ligate the appropriate fragments to form the correct coding sequence. Translational initiation codon ATG and termination codon TAA were provided at the appropriate ends of the protease gene. A sequence was added to provide a protrusion at the 5' end of the gene, having a cohesive end compatible to the restriction enzyme site Ncol. The 5' protrustion at the 3' end of the gene was added to provide a Hind3 compatible end. The complementary strands (not shown) were provided with 3' overhangs to match the coding strands.
EXPRESSION OF THE SYNTHETIC HIV-1 PROTEASE GENE IN E. COLI
Three clones (PR-C, PR-H, and PR-J) bearing the correct coding sequence of 297bp in the expression vector PKK233-2 were analyzed for expression to select conditions for the optimal induction of the gene.
Figure 3 shows examples of Western blot analysis of the gene product.
Figure 3 illustrates expression of the synthetic protease gene in E. coli. Clone PR-C bearing the coding sequence to the protease was induced for expression. The proteins (75ug of bacterial extract) were electrophoresed in a NaDodSO4/PAGE transferred to nitrocellulose and subjected to immunoblot analysis using a mixture of the two protease specific rabbit polyclonal antibodies raised against (i) a complete synthetic sequence of 1-99 amino acids of the HIV-1 protease and (ii) a tridecapeptide corresponding to the C terminus of the protease. Figure 3A shows the induction of the gene with 0.4mM IPTG at various periods of time. Figure 3B shows the induction for 30 minutes. With increasing concentrations of inducer IPTG. 1-5 represent mM concentration of IPTG at 0.28, 0.56, 1.12, 2.24 and 4.48 respectively. Figure 3C shows the analysis after 60 minutes of induction with ImM IPTG and lysing the cells in various buffers. B1 denotes lysis of cells in 50mM Tris-HCl at pH 7.0, 150mM NaCl, ImM EDTA, ImM PMST, ImM DTT and 0.5 percent NP-40. B2 is the same as B1, but without NaCl and
EDTA. B3 is in 50mM potassium phosphate at pH 6.0, ImM PMSF and ImM DTT. B4 is the same as B3 with a pH of 6.5. Positions of protein molecular weight markers are inducated on the left in kilodaltons.
E. coli cells bearing plasmid PR-C were grown in Luria broth to an optical density of 0.4 A600nm, and then induced at various periods of time for expression from the trc promotor by adding IPTG (isopropyl-beta-D-thiog-alactopyranoside) at a concentration of 0.4mM as seen in Figure 3A. The cloned gene expressed a single, unfused protein band of 11.5kd. Expression was maximal after 30 minutes of induction. This level decreased to about 25 percent at 60 minutes. There was no
detectable expression after 120 minutes of induction and at 0 minutes. This pattern of induction was similar in the other clones (PR-H and PR-J) that were analyzed (not shown).
The results of the induction for 30 minutes with varying concentrations of inducer are shown in
Figure 3B. Induction with IPTG in the range of ImM to 4mM resulted in maximum amount of expression. Similar data were obtained on clones PR-H and PR-J (not shown).
In order to select the conditions that efficiently solubilize the protease for enzymatic analysis, different buffer systems were used for the lysis of cells (clone PR-C) after optimal induction with ImM IPTG. It was observed that sonication in a buffer system of 50mM Tris-cl at pH 7.5, ImM DTT, ImM PMSF and 0.5% nonidet P-40 released 50 to 70 percent of the protease in the soluble fraction (Figure 3C). This was estimated by Western blot analysis aliquots of soluble extract and insoluble pellet for the content of the expressed product. DEMONSTRATION OF SPECIFIC PROTEOLYTIC ACTIVITY
Figure 4 illustrates the activity of the expressed protease using a synthetic peptide as a substrate. Protease assays were carried out with
22.5ug of bacterial lysate at 37°C obtained from clone PR-C, induced (A,B,C), uninduced (D), and control cells bearing just the plasmid PKK233-2 (data not shown). The nonapeptide was used as a substrate in reaction buffer (0.25 M potassium phosphate), pH 7.0, 0.5 percent (v/v) NP 40, 5 percent (v/v) glycerol, 5 inM
Dithiotreit and 2 M NaCl. Aliquots of 25 ul each were taken at 0 hours (A), 1 hour (B) 3 hours (C) and 6 hours (D) analyzed by RP-HPLC. S denotes the substrate and P1 and P2, cleavage products 1 and 2 respectively.
To assess the activity of the cloned HIV-1
Protease a synthetic nonapeptide corresponding to the HIV-1 pl7-p24 cleavage site (Henderson, et al. 1988) was used as a substrate (4E). The substrate in
reaction buffer was mixed with aliquots of various cell extracts (see description of Figure 4 above) and incubated at 37°C. Equal eliquots of incubation mixture were taken at various time points and analyzed by RP-HPLC. The substrate in the 0 hour sample eluted as a single peak as shown in Figure 4A. After incubation for 1 hour, two newly appearing peaks, products
labelled P1 and P2, can be seen, correlating with a significant decrease of the substrate peak. Subsequent amino acid analysis of the recovered peaks demonstrated that product 1 and product 2 corresponded to the expected cleavage products as shown in Table 1 proving a Tyr-Pro bond cleavage, which is the determined natural cleavage site. Extended incubation for 3 hours showed a further decrease of the substrate peak and substantial increase in the peak height of product 1, indicating progression of the hydrolysis of the Tyr-Pro bond. However, the peak of product 1 seems to be smaller as expected since the absorbance of the
tetrapeptide Pro-Ile-Val-Glu-NH2 is substantially smaller than that of the pentapeptide having a free
COOH-terminal tyrosine. An increase of product 1 and 2 after 3 hours of incubation showed a corresponding decrease of the substrate peak.
No cleavage products have been detected in reactions using extracts from uninduced cells, clone PR-C (Figure 4D) and of control cells (control plasmid PKK233-2; data not shown). There was no decrease in the substrate peak even after 6 hours of incubation (Figure 4D) indicating that the nonapeptide is
resistent to degradation by bacterial proteases. This makes this substrate especially useful for assaying viral protease activities in crude extracts,
facilitating purification and isolation of the
protease.
The amino acid composition data for the substrate and its cleavage products are shown in Table 1. The amounts of observed amino acids correspond clearly to the expected amounts demonstrating that the cleavage occurs at the expected cleavage site of the synthetic peptide corresponding to the pl7-p24 site of the gag precursor.
Table 1. Amino add composition of the substrate and the cleavage products
Amino acids Substrate product 1 product 2
Predicted Recovered Predicted Recovered Predicted Recovered
Asp 1 1.06 0 0.01 1 0.94
Glu 2 2.06 1 1.00 1 1.00
Ser 1 0.98 0 0.01 1 0.89
Pro 1 1.05 1 1.19 0 0.03
Tyr 1 1.06 0 0.01 1 1.01
Val 2 1.87 1 0.43* 1 1.16 Ile 1 0.92 1 0.45* 0 0.02
*The observed amounts of Val and Ile were found lower than expected in product 1 due to a frequently observed Inefficient hydrolysis of the Ile-Val bond.

Claims

IN THE CLAIMS
1. A gene for encoding a protease of human immunodeficiency virus consisting essentially of:
a synthetic nucleotide sequence for a
protease essential to infectivity of human
immunodeficiency virus.
2. The gene of claim 1 wherein said protease is essential for infectivity of a retrovirus.
3. The gene of claim 2 wherein said retrovirus is a member of the group consisting of HIV-1, HIV-2, and HTLV a Human Leukemia virus.
4. A gene for encoding a protease of human immunodeficiency virus consisting essentially of:
a synthetic double stranded nucleotide sequence of which the coding sequence is:
10 20 30 40 50
CCTCAGATCA CTCTTTGGCA ACGACCCCTC GTCACAATAA AGATAGGGGG
60 70 80 90 100
GCAACTAAAG GAAGCTCTAT TAGATACAGG AGCAGATGAT ACAGTATTAG
110 120 130 140 150
AAGAAATGAG TTTGCCAGGA AGATGGAAAC CAAAAATGAT AGGGGGAATT
160 170 180 190 200
GGAGGTTTTA TCAAAGTAAG ACAGTATGAT CAGATACTCA TAGAAATCTG
210 220 230 240 250 TGGACATAAA GCTATAGGTA CAGTATTAGT AGGACCTACA CCTGTCAACA
260 270 280 290
TAATTGGAAG AAATCTGTTG ACTCAGATTG GTTGCACTTT AAATTTT
5. A method for expressing a protease consisting essentially of inserting a recombinant vector containing a synthetic gene for a protease essential for infectivity of a retrovirus into a host cell;
expressing said gene; and
separating said protease.
6. The process of claim 5 wherein said retrovirus is a member of the group consisting of HIV-1, HIV-2, and HTLV a Human Leukemia virus.
7. The process of claim 5 wherein said retrovirus is HIV-1 and said gene has a nucleotide sequence of
10 20 30 40 50
CCTCAGATCA CTCTTTGGCA ACGACCCCTC GTCACAATAA AGATAGGGGG
60 70 80 90 100
GCAACTAAAG GAAGCTCTAT TAGATACAGG AGCAGATGAT ACAGTATTAG
110 120 130 140 150
AAGAAATGAG TTTGCCAGGA AGATGGAAAC CAAAAATGAT AGGGGGAATT
160 170 180 190 200
GGAGGTTTTA TCAAAGTAAG ACAGTATGAT CAGATACTCA TAGAAATCTG
210 220 230 240 250
TGGACATAAA GCTATAGGTA CAGTATTAGT AGGACCTACA CCTGTCAACA
260 270 280 290
TAATTGGAAG AAATCTGTTG ACTCAGATTG GTTGCACTTT AAATTTT
PCT/US1989/002996 1988-07-13 1989-07-13 Synthetic hiv protease gene and method for its expression WO1990000556A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21830488A 1988-07-13 1988-07-13
US218,304 1988-07-13

Publications (1)

Publication Number Publication Date
WO1990000556A1 true WO1990000556A1 (en) 1990-01-25

Family

ID=22814563

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/002996 WO1990000556A1 (en) 1988-07-13 1989-07-13 Synthetic hiv protease gene and method for its expression

Country Status (6)

Country Link
EP (1) EP0425580A4 (en)
JP (1) JPH04500602A (en)
AU (1) AU635216B2 (en)
CA (1) CA1340748C (en)
IL (1) IL90947A (en)
WO (1) WO1990000556A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599789A (en) * 1991-12-24 1997-02-04 Amrad Corporation Limited Method for the treatment of tumours and sarcomas
EP0887427A3 (en) * 1997-06-25 2001-10-17 Ortho-Clinical Diagnostics, Inc. Amplification and detection of hiv-1 and/or hiv-2
US6602705B1 (en) 1998-12-31 2003-08-05 Chiron Corporation Expression of HIV polypeptides and production of virus-like particles
US7662916B2 (en) 1998-12-31 2010-02-16 Novartis Vaccines & Diagnostics, Inc Modified HIV Env polypeptides
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US7943375B2 (en) 1998-12-31 2011-05-17 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US8263394B2 (en) 1998-12-31 2012-09-11 Novartis Vaccines & Diagnostics Inc. Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides, and uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07504654A (en) * 1992-03-11 1995-05-25 ナルヘックス　リミテッド Amine derivatives of oxo- and hydroxy-substituted hydrocarbons
US6071895A (en) * 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
DE69333270T2 (en) 1992-03-11 2004-08-05 Narhex Ltd. AMINE DERIVATIVES OF OXO AND HYDROXY SUBSTITUTED CARBON HYDROGEN
US5888992A (en) * 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252477A (en) * 1987-06-01 1993-10-12 The United States Of America As Represented By The United States Department Of Health And Human Services Human immunodeficiency virus specific proteolytic enzyme and a method for its synthesis and renaturation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cell, Volume 40, published January 1985. S. WAIN-HOBSON, et al. "Nucleotide Sequence of the AIDS Virus, LAV," pp. 9-17. see section entitled "Pol" and figures 1-4 *
Nature, Volume 313, published 24 January, 1985. L. RATNER, et al. "Complete Nucleotide Sequence of the AIDS Virus, HTLV-III," pp. 277-284. see section "Second open Reading Frame", discussion section and figures 1-4. *
Proc. Natl. Acad. Sci. USA, Volume 84, published December 1987. C. DEBOUK, et al. "Human Immunodeficiency Virus Protease Expressed in Escherichia Coli Exhibits Autoprocessing and Specific Maturation of the Gag Precursor," pp. 8903-8906. see entire article *
Science, Volume 236, published 17 April 1987. W. FARMERIE, et al, "Expression and Processing of the AIDS Virus Reverse Transcriptase in E. Coli," pp. 305-308. see entire article *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599789A (en) * 1991-12-24 1997-02-04 Amrad Corporation Limited Method for the treatment of tumours and sarcomas
EP0887427A3 (en) * 1997-06-25 2001-10-17 Ortho-Clinical Diagnostics, Inc. Amplification and detection of hiv-1 and/or hiv-2
US6602705B1 (en) 1998-12-31 2003-08-05 Chiron Corporation Expression of HIV polypeptides and production of virus-like particles
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles
US7662916B2 (en) 1998-12-31 2010-02-16 Novartis Vaccines & Diagnostics, Inc Modified HIV Env polypeptides
US7718401B2 (en) 1998-12-31 2010-05-18 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US7943375B2 (en) 1998-12-31 2011-05-17 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US8168418B2 (en) 1998-12-31 2012-05-01 Susan W Barnett Expression of HIV polypeptides and production of virus-like particles
US8263394B2 (en) 1998-12-31 2012-09-11 Novartis Vaccines & Diagnostics Inc. Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides, and uses thereof

Also Published As

Publication number Publication date
IL90947A (en) 1997-06-10
IL90947A0 (en) 1990-02-09
EP0425580A1 (en) 1991-05-08
CA1340748C (en) 1999-09-14
AU635216B2 (en) 1993-03-18
AU4058589A (en) 1990-02-05
JPH04500602A (en) 1992-02-06
EP0425580A4 (en) 1992-05-06

Similar Documents

Publication Publication Date Title
Feng et al. HIV-1 nucleocapsid protein induces" maturation" of dimeric retroviral RNA in vitro.
Kräusslich et al. Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides.
Le Grice et al. Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation.
Kräusslich Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity.
Ohno-Iwashita et al. Assignment of the functional loci in colicin E2 and E3 molecules by the characterization of their proteolytic fragments
Tomasselli et al. Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2.
Copeland et al. Genetic locus, primary structure, and chemical synthesis of human immunodeficiency virys protease
DiIanni et al. Characterization of an active single polypeptide form of the human immunodeficiency virus type 1 protease.
Louis et al. Autoprocessing of the HIV‐1 protease using purified wild‐type and mutated fusion proteins expressed at high levels in Escherichia coli
Strickler et al. Characterization and autoprocessing of precursor and mature forms of human immunodeficiency virus type 1 (HIV 1) protease purified from Escherichia coli
CA1340748C (en) Synthetic hiv protease gene and method for its expression
Wondrak et al. The gag precursor contains a specific HIV‐1 protease cleavage site between the NC (P7) and P1 proteins
Louis et al. Chemical synthesis and expression of the HIV-1 protease gene in E. coli
US5354683A (en) Human immunodeficiency virus specific proteolytic enzyme and a method for its synthesis and renaturation
DEIBEL JR et al. Denaturation/refolding of purified recombinant HIV reverse transcriptase yields monomeric enzyme with high enzymatic activity
Tanese et al. Structural requirements for bacterial expression of stable, enzymatically active fusion proteins containing the human immunodeficiency virus reverse transcriptase
Tomasselli et al. Calcium‐free calmodulin is a substrate of proteases from human immunodeficiency viruses 1 and 2
Tomasselli et al. Interdomain hydrolysis of a truncated Pseudomonas exotoxin by the human immunodeficiency virus-1 protease.
Pfrepper et al. Expression and molecular characterization of an enzymatically active recombinant human spumaretrovirus protease
Menendez-Arias et al. Purification and characterization of the mouse mammary tumor virus protease expressed in Escherichia coli.
Louis et al. Substitution mutations of the highly conserved arginine 87 of HIV-1 protease result in loss of proteolytic activity
Schnölzer et al. Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis
US5637488A (en) HIV protease gene and method for its expression
Schulze et al. Cleavage of the HIV-1 p66 reverse transcriptase/RNase H by the p9 protease in vitro generates active p15 RNase H
CA2004646C (en) Protease, reverse transcriptase and endonuclease of retrovirus, and method for producing these enzymes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989909316

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989909316

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1989909316

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1989909316

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载